The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the Brain
Open Access
- 17 September 2019
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (3) , 138
Abstract
Iron chelation therapy, either subcutaneous or orally administered, has been used successfully in various clinical conditions. The removal of excess iron from various tissues, e.g., the liver spleen, heart, and the pituitary, in beta thalassemia patients, has become an essential therapy to prolong life. More recently, the use of deferiprone to chelate iron from various brain regions in Parkinson’s Disease and Friederich’s Ataxia has yielded encouraging results, although the side effects, in <2% of Parkinson’s Disease(PD) patients, have limited its long-term use. A new class of hydroxpyridinones has recently been synthesised, which showed no adverse effects in preliminary trials. A vital question remaining is whether inflammation may influence chelation efficacy, with a recent study suggesting that high levels of inflammation may diminish the ability of the chelator to bind the excess iron.Keywords
This publication has 80 references indexed in Scilit:
- Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine MonotherapyJournal of Cardiovascular Magnetic Resonance, 2013
- Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound ironAmerican Journal of Physiology-Cell Physiology, 2011
- Study of the effect of iron overload on the function of endocrine glands in male thalassemia patientsAsian Journal of Transfusion Science, 2011
- Structural bases for the interaction of frataxin with the central components of iron–sulphur cluster assemblyNature Communications, 2010
- Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s DiseaseNeurotoxicity Research, 2009
- Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemiaEuropean Journal of Haematology, 2009
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questionsBlood, 2006
- Iron Deposition in the Anterior Pituitary in Homozygous Beta-Thalassemia: MRI Evaluation and Correlation with Gonadal FunctionJournal of Pediatric Endocrinology and Metabolism, 2000
- INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAINThe Lancet, 1987
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977